Breast Cancer Exosome-Derived miR-425-5p Induces Cancer-Associated Fibroblast-Like Properties in Human Mammary Fibroblasts by TGFβ1/ROS Signaling Pathway

Copyright © 2022 Yue Zhu et al..

The connection between the cellular microenvironment and tumor cells is crucial for tumor progression. However, the process by which normal fibroblasts (NFs) become cancer-associated fibroblasts (CAFs) is unknown, and mounting evidence suggests that some microRNAs (miRNAs) have an important role in converting NFs into CAFs. Breast cancer (BC) has been proven to have enhanced miR-425-5p expression in order to support progression. We discovered that human mammary fibroblasts (HMFs) could uptake BC cell line-derived exosomes to change their properties, promoting the switch to the CAF phenotype and increasing cell motility, as evidenced by an increase in CAF activation-related marker protein expression and cell proliferation, invasion, and migration. Transfection of exosomes is obtained from BC cells, and miR-425-5p inhibitors suppressed the aforementioned effects as well as lowered chemokine levels and gene expression related with proliferation and metastasis. By suppressing the expression of its target gene TGFβRII (TGFβ1 receptor), miR-425-5p enhanced the transition of HMFs to the CAF phenotype. MDA-MB-231 cells and CAFs stimulated by HMF absorption of MDA-MB-23-derived exosomes showed similar proliferation, invasion, migration, and expression of -SMA, FAP, CXCL1, IL-6, TGFβ1, P21, P27, Ki67, vimentin, E-cadherin, N-cadherin, α-catenin, fibronectin, and MMP-2. TGFβ1 overexpression enhanced ROS production. Finally, we found that HMFs transiently transfected with miR-425-5p can promote tumor growth in vivo. Finally, these findings provide fresh insight on miR-425-5p as an important mediator of the interaction between BC cells and stroma.

Errataetall:

RetractionIn: Oxid Med Cell Longev. 2023 Jun 21;2023:9857678. - PMID 37388516

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:2022

Enthalten in:

Oxidative medicine and cellular longevity - 2022(2022) vom: 01., Seite 5266627

Sprache:

Englisch

Beteiligte Personen:

Zhu, Yue [VerfasserIn]
Dou, He [VerfasserIn]
Liu, Yuqi [VerfasserIn]
Yu, Pingyang [VerfasserIn]
Li, Fucheng [VerfasserIn]
Wang, Youyu [VerfasserIn]
Xiao, Min [VerfasserIn]

Links:

Volltext

Themen:

Journal Article
MIRN425 microRNA, human
MicroRNAs
Retracted Publication

Anmerkungen:

Date Completed 14.12.2022

Date Revised 30.06.2023

published: Electronic-eCollection

RetractionIn: Oxid Med Cell Longev. 2023 Jun 21;2023:9857678. - PMID 37388516

Citation Status MEDLINE

doi:

10.1155/2022/5266627

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM350191204